**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 84676

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders**

Dybowska D *et al*. DAA in mentally ill HCV patients

Dorota Dybowska, Dorota Zarębska-Michaluk, Piotr Rzymski, Hanna Berak, Beata Lorenc, Marek Sitko, Michał Dybowski, Włodzimierz Mazur, Magdalena Tudrujek-Zdunek, Justyna Janocha-Litwin, Ewa Janczewska, Jakub Klapaczyński, Anna Parfieniuk-Kowerda, Anna Piekarska, Barbara Sobala-Szczygieł, Krystyna Dobrowolska, Malgorzata Pawłowska, Robert Flisiak

**Dorota Dybowska, Malgorzata Pawłowska,** Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, Bydgoszcz 85-030, Poland

**Dorota Zarębska-Michaluk,** Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce 25-317, Poland

**Dorota Zarębska-Michaluk,** Department of Infectious Diseases, Provincial Hospital, Kielce 25-317, Poland

**Piotr Rzymski,** Department of Environmental Medicine, University of Medical Sciences, Poznań 60-806, Poland

**Piotr Rzymski,** Integrated Science Association, Universal Scientific Education and Research Network, Poznań 60-806, Poland

**Hanna Berak,** Outpatient Clinic, Hospital for Infectious Diseases in Warsaw, Warsaw 01-201, Poland

**Beata Lorenc,** Pomeranian Center of Infectious Diseases, Medical University, Gdańsk 80-214, Poland

**Marek Sitko,** Department of Infectious and Tropical Diseases, Jagiellonian University, Kraków 31-088, Poland

**Michał Dybowski,** Utrecht University School of Economics, Utrecht University, Utrecht 3584 EC, Netherlands

**Włodzimierz Mazur,** Clinical Department of Infectious Diseases, Medical University of Silesia, Chorzów 41-500, Poland

**Magdalena Tudrujek-Zdunek,** Department of Infectious Diseases, Medical University of Lublin, Lublin 20-059, Poland

**Justyna Janocha-Litwin,** Department of Infectious Diseases and Hepatology, Medical University of Wrocław, Wrocław 50-367, Poland

**Ewa Janczewska,** Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia, Katowice 40-007, Poland

**Jakub Klapaczyński,** Department of Internal Medicine and Hepatology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw 00-241, Poland

**Anna Parfieniuk-Kowerda, Robert Flisiak,** Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok 15-089, Poland

**Anna Piekarska,** Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź 91-347, Poland

**Barbara Sobala-Szczygieł,** Department of Infectious Diseases and Hepatology, Medical University of Silesia, Bytom 41-902, Poland

**Krystyna Dobrowolska,** Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland

**Author contributions:** Dybowska D, Zarębska-Michaluk D, Rzymski P, Pawłowska M and Flisiak R conceived the study design; Dybowska D and Dybowski M cured data and prepared data for analysis; Dybowska D and Rzymski P analyzed and interpreted the data; Rzymski P performed the statistical analysis; Rzymski P prepared tables and figures; Dybowska D, Zarębska-Michaluk, Rzymski P, Pawłowska M, and Flisiak R drafted the manuscript; Dobrowolska K prepared the manuscript for submission; Berak H, Lorenc B, Sitko M, Dybowski M, Mazur W, Tudrujek-Zdunek M, Janocha-Litwin J, Janczewska E, Klapaczyński J, Parfieniuk-Kowerda A, Piekarska A, Sobala-Szczygieł Barbara, Dobrowolska K, and Pawłowska M acquired the data and approved the final version of the manuscript.

**Corresponding author: Dorota Zarębska-Michaluk, PhD, Assistant Professor, Professor,** Department of Infectious Diseases and Allergology, Jan Kochanowski University, Żeromskiego 5, Kielce 25-317, Poland. dorota1010@tlen.pl

**Received:** March 23, 2023

**Revised:** April 1, 2023

**Accepted:** April 28, 2023

**Published online:** July 7, 2023

**Abstract**

BACKGROUND

It is estimated that 58 million people worldwide are infected with the hepatitis C virus (HCV). Patients with severe psychiatric disorders could not be treated with previously available interferon-based therapies due to their unfavorable side effect profile. This has changed with the introduction of direct-acting antivirals (DAA), although their real-life tolerance and effectiveness in patients with different psychiatric disorders remain to be demonstrated.

AIM

To evaluate the effectiveness and safety of DAA in patients with various mental illnesses.

METHODS

This was a retrospective observational study encompassing 14272 patients treated with DAA for chronic hepatitis C in 22 Polish hepatology centers, including 942 individuals diagnosed with a mental disorder (anxiety disorder, bipolar affective disorder, depression, anxiety-depressive disorder, personality disorder, schizophrenia, sleep disorder, substance abuse disorder, and mental illness without a specific diagnosis). The safety and effectiveness of DAA in this group were compared to those in a group without psychiatric illness (*n* = 13330). Antiviral therapy was considered successful if serum ribonucleic acid (RNA) of HCV was undetectable 12 wk after its completion [ (sustained virologic response (SVR)]. Safety data, including the incidence of adverse events (AEs), serious AEs (SAEs), and deaths, and the frequency of treatment modification and discontinuation, were collected during therapy and up to 12 wk after treatment completion. The entire study population was included in the intent-to-treat (ITT) analysis. Per-protocol (PP) analysis concerned patients who underwent HCV RNA evaluation 12 wk after completing treatment.

RESULTS

Among patients with mental illness, there was a significantly higher percentage of men, treatment-naive patients, obese, human immunodeficiency virus and hepatitis B virus-coinfected, patients with cirrhosis, and those infected with genotype 3 (GT3) while infection with GT1b was more frequent in the population without psychiatric disorders. The cure rate calculated PP was not significantly different in the two groups analyzed, with a SVR of 96.9% and 97.7%, respectively. Although patients with bipolar disorder achieved a significantly lower SVR, the multivariate analysis excluded it as an independent predictor of treatment non-response. Male sex, GT3 infection, cirrhosis, and failure of previous therapy were identified as independent negative predictors. The percentage of patients who completed the planned therapy did not differ between groups with and without mental disorders. In six patients, symptoms of mental illness (depression, schizophrenia) worsened, of which two discontinued treatments for this reason. New episodes of sleep disorders occurred significantly more often in patients with mental disorders. Patients with mental illness were more frequently lost to follow-up (4.2% *vs* 2.5%).

CONCLUSION

DAA treatment is safe and effective in HCV-infected patients with mental disorders. No specific psychiatric diagnosis lowered the chance of successful antiviral treatment.

**Key Words:** Hepatitis C; Mental disorders; Direct-acting antivirals

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Dybowska D, Zarębska-Michaluk D, Rzymski P, Berak H, Lorenc B, Sitko M, Dybowski M, Mazur W, Tudrujek-Zdunek M, Janocha-Litwin J, Janczewska E, Klapaczyński J, Parfieniuk-Kowerda A, Piekarska A, Sobala-Szczygieł B, Dobrowolska K, Pawłowska M, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders. *World J Gastroenterol* 2023; 29(25): 4085-4098

**URL:** <https://www.wjgnet.com/1007-9327/full/v29/i25/4085.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v29.i25.4085

**Core Tip:** In the population of patients with mental illness, the prevalence of hepatitis C virus infection is many times higher than in the general population. In the era of interferon-based therapy, these patients had minimal access to antiviral treatment due to contraindications to interferon with the risk of exacerbation of psychiatric diseases. Their situation has improved with the introduction of direct-acting antivirals, but data from real-world studies are scarce. This retrospective analysis carried out in clinical practice confirmed that the good safety profile and treatment effectiveness are not inferior to those obtained in a population without mental disorders.

**INTRODUCTION**

Hepatitis C virus (HCV) infection, currently affecting approximately 58 million individuals worldwide, still poses a severe global issue[1]. It remains a major cause of chronic liver disease worldwide, liable to progress to cirrhosis and hepatocellular carcinoma, and can lead to various extrahepatic manifestations[2]. The prevalence of HCV infection is significantly increased (3-fold to 20-fold) in individuals with mental disorders compared to the general population. This includes patients with depression, bipolar disorder, schizophrenia, and personality disorders. In patients with substance abuse, particularly with intravenous drug use, the reported percentage of HCV infection is as high as 60%-70%[3,4]. In addition, preexisting mental illness may complicate HCV treatment by adversely affecting treatment adherence[5-7]. Moreover, HCV infection itself can further exacerbate or accelerate psychiatric symptoms[6,8].

In the past, treatment of patients with severe psychiatric disorders infected with HCV was highly challenging due to neuropsychiatric side effects (*e.g.,* anxiety, affective, cognitive, and psychotic symptoms) of previously used interferon (IFN)-based therapies[9]. Their situation has improved with the introduction of direct-acting antivirals (DAA), which are well tolerated and easier to dose[10]. Whether they are also effective in different mental disorders requires further studies. Observations from the IFN-era period indicate that these disorders were not necessarily associated with a worse sustained viral response (SVR) rate[11-13]. However, the observations encompassingthe period when DAA were introduced are scarce, include small study groups, only particular diseases (*e.g.,* depression), or treat them collectively as mental disorders[14-17]. The results of one multicenter study evaluating a single DAA regimen among psychiatric patients by type of mental disorder have recently been published, but evidence is still needed from large populations of real-world experience that discriminate between individual psychiatric diseases treated with different DAA options and compare the results to the group without mental disorders while controlling for confounding variables[18].

To this end, the present study aimed to evaluate the effectiveness and safety of DAA in patients with various mental illnesses: Anxiety, anxiety-depressive disorder, bipolar disorder, depression, personality disorder, schizophrenia, sleep disorder, substance abuse, and mental illness without a specific diagnosis. In order to achieve this goal, a retrospective, real-world analysis of the Polish population of HCV-infected patients treated with DAA between 2015 and 2022 was conducted.

**MATERIALS AND METHODS**

***Data collection***

The data of 14272 patients treated with DAA for chronic hepatitis C (CHC) from 1 July 2015 to 30 December 2022, included in the EpiTer-2 observational study database, were analyzed. This study was conducted under the auspices of the Polish Association of Epidemiologists and Infectiologists and included data from 22 Polish hepatology centers on treating CHC in everyday practice. The choice of CHC therapy was at the physician’s discretion and followed the existing recommendations of the Polish Group of Experts for HCV and the recommendations of the National Health Fund. The data were collected retrospectively and included age, sex, body mass index, the severity of liver disease, HCV genotype (GT), human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) coinfection, previous and current CHC treatment, presence of hepatocellular carcinoma, HCV viral load, alanine transaminase activity, albumin, hemoglobin, creatinine, and platelets level.

***Assessment of mental disorders***

The patients were divided into two groups: 942 patients with concomitant mental illness (group A) and 13330 without psychiatric disorders (group B). Mentally ill patients were under the care of psychiatrists, who diagnosed their mental illness, prescribed and monitored psychiatric treatment.

***Assessment of liver disease severity***

The severity of liver disease was assessed using non-invasive methods of fibrosis assessment: Transient elastography or shear-wave elastography with an Aixplorer device (SuperSonic Imagine, Aix-en-Provence, France) or transient FibroScan. Based on the METAVIR score, according to the guidelines of the European Association for the Study of the Liver, the cutoff value of 13 kPa was used to predict individuals considered to be cirrhotic[19]. These patients were evaluated for the presence of decompensation of liver function (in the past and at the beginning of antiviral therapy) and were assessed on the Child-Pugh (CP) scale. Patients scored as B or C on the CP scale were considered to be decompensated. Data were also collected on the past diagnosis of HCC and liver transplantation.

***Effectiveness assessment***

Antiviral therapy was considered successful if ribonucleic acid of the virus (HCV RNA) in serum was undetectable 12 wk after its completion, meaning that the patient achieved a sustained virologic response (SVR). Patients with detectable viral load at this time point were considered virologic failures, while those lost to follow-up without HCV RNA evaluation 12 wk after the end of therapy were recognized as non-virological failures and not included in the PP analysis.

***Safety assessment***

An analysis of potential drug-drug interactions was carried out before the start of DAA therapy using an online tool on the University of Liverpool website[20]. The results of this analysis influenced the choice of DAA regimen or modification of psychiatric therapy. Safety data, including the incidence of adverse events (AEs), serious AEs (SEAs), and deaths, as well as the frequency of treatment modification and discontinuation, were collected during therapy and up to 12 wk after treatment completion.

***Ethics***

The data were originally collected not for scientific purposes but to evaluate the effectiveness and safety of real-world treatment with registered drugs. Patients were not exposed to any experimental interventions. According to local law (Law of 6 September 2001, Pharmaceutical Law, Article 37al), non-interventional studies do not require ethics committee approval. Due to the retrospective design of the analysis, the requirement for patient consent was not necessary. Patient data were collected and analyzed in accordance with applicable data protection rules.

***Statistical analysis***

Statistical analyses were performed using Statistica v. 13 (StatSoft, Tulsa, OK, United States) and MedCalc v. 15.8 (MedCalc Software Ltd, Ostend, Belgium). The entire study population was included in the ITT analysis. The PP analysis concerned patients who underwent HCV RNA evaluation 12 wk after completing treatment.Differences in frequencies of events between groups with and without mental disorders were assessed with *χ2* Pearson’s test or Fisher exact test (when the number of observations was < 10). The differences in data expressed on the interval scale were evaluated with a non-parametric Mann-Whitney *U* test because they did not meet the Gaussian assumption (Shapiro-Wilk’s test, *P* < 0.05). Multiple logistic regression was used to predict the odds of no response to HCV treatment for mental disorders (for which a lower frequency of SVR was observed) while controlling for known factors affecting the chance of SVR in the IFN and IFN-free era: male sex, obesity, GT3, cirrhosis, history of HCV treatment failure, HIV coinfection, HBV coinfection, and three antiviral combinations: asunaprevir (ASV) and daclatasvir (DCV), sofosbuvir (SOF) and velpatasvir (VEL), and SOF/VEL with ribavirin (RBV)[21-24]. A *P*-value below 0.05 was deemed statistically significant.

**RESULTS**

***Characteristics of the studied groups***

The demographic characteristics of the groups are summarized in Table 1. Group A included 503 patients who had depression (55.6%), 121 with schizophrenia (12.8%), 36 with mental illness without a specific diagnosis (3.8%), 26 with anxiety-depressive disorders (2.8%), 24 with bipolar affective disorder (2.6%), 21 with anxiety disorders (2.2%), 16 with personality disorders (1.7%), and 6 with sleep disorders (0.6%). Substance abuse disorder was diagnosed in 159 cases (16.9%). Moreover, in 30 patients (3.2%), substance abuse and other mental illness coexisted: Depression in 21 patients (2.2%), personality disorders in 4 (0.4%), schizophrenia in 2 (0.2%), anxiety disorders in 2 (0.2%), and an anxiety-depressive disorder in 1 patient (0.1%).

The mean age of patients in both groups was comparable. Group A included a higher percentage of men, obese individuals, patients with more advanced liver fibrosis, and a higher percentage of CP class B and C patients. Similar to group B, the GT1b prevailed, although its frequency was lower, while the higher percentage of HCV-infections with GTs 3 and 4 were noted. Coinfections with HIV and/or HBV were also more common in the group of patients with mental disorders (Table 2).

This group was also characterized by a higher baseline HCV viral load. Most patients in group A (80.6%) were treatment-naïve, while 16.7% (*n* = 157) of the cases had previously been treated with IFN. Of these, 34 patients discontinued IFN-based therapy due to AEs. During current therapy, 12/34 (35%) had mild AEs, the most common of which was headache (*n* = 3), and one patient in this group experienced increased insomnia. All patients in this group completed therapy as planned, 31 achieved SVR, and 1 patient was lost to follow-up. Patients with mental illnesses were more often treated with pangenotypic therapy for CHC (Table 3).

***Treatment effectiveness***

There were no statistically significant differences in the achievement of SVR in groups A and B in both the ITT (92.8% *vs* 95.3%, respectively) and PP (96.9% *vs* 97.7%) analyses (Figure 1A). A significantly lower percentage of SVR was observed in patients with bipolardisorder (Figure 1B). In multivariate analyses, a lower chance of SVR was associated with male sex, GT3, cirrhosis, history of previous HCV-treatment failure, and two DAA regimens: ASV + DCV and SOF + VEL + RBV (Table 4).

***Treatment safety***

Patients with mental illness more often belonged to the group lost to follow-up (4.2% *vs* 2.5%). In six patients symptoms of mental illness (depression - 5, schizophrenia - 1) worsened during antiviral therapy, of which two permanently discontinued treatment for this reason. New episodes of sleep disorders occurred significantly more often in group A during DAAtherapy. In group B, one patient experienced an episode of schizophrenia, and six were diagnosed with depression. In both groups, a similar percentage of patients completed the planned treatment. There were no statistically significant differences in discontinued and modified treatments (Table 5).

Modification of therapy concerned only a change in the dose of RBV. Possible drug interactions were analyzed prior to antiviral therapy. Patients in group A were treated with neuroleptics, anticonvulsants, antidepressants, sedatives, anxiolytics, and methadone. Only carbamazepine could have clinically relevant interactions. This drug was used in 3 patients in group A and in 12 patients in group B. All patients with mental diseases using carbamazepine completed the treatment as planned without AEs, and all achieved SVR.

**DISCUSSION**

By documenting the high rate of SVR in patients with mental diseases, our study proves that this patient population does not differ in their response to DAA treatment from those with CHC not affected by psychiatric conditions supporting the findings of a recently published multicenter analysis[18]. Thus, there is no rationale for considering these patients as a difficult-to-treat population in terms of virologic response to therapy, as they were previously recognized in the era of IFN-based regimens. Antiviral therapy for mentally ill patients has been a challenge due to contraindications to the use of IFN and the side effects of this cytokine[9,25]. Neuropsychiatric disorders of various caliber during IFN therapy have been widely reported[26-28]. Most were mild in severity and transient in nature, but severe psychosis and suicide attempts have also been described as a reason for discontinuing therapy. Such side effects of therapy have been described even in patients with no prior mental disorders[29]. Due to the risk of exacerbating psychiatric conditions, many patients with a diagnosed mental illness were not eligible for treatment. The mental state of those included in therapy had to be closely monitored, requiring cooperation with the patient’s attending psychiatrist[30]. This was the only way to keep the patient in therapy and in the event of exacerbation of mental disorders, to react swiftly and to modify or discontinue antiviral treatment, if necessary for safety reasons[5,31]. At the same time, this was a population of patients in whom successful antiviral therapy offered a chance for mental improvement[32]. In addition to causing liver disease, HCV can potentially induce extrahepatic manifestations, *i.e.,* disorders of other organs and systems that are pathogenetically associated with infection[33]. One of them is the central nervous system, whose involvement results in neurological and psychiatric disorders[6,7,34]. The mechanism of the virus’s impact on the nervous system is complex and includes both a direct cytopathic effect related to the infection of nerve cells, as well as the impact of the immune response triggered by the HCV and the effects of psychogenic stressors[8,34,35].

The frequent co-occurrence of CHC and psychiatric disorders was confirmed by numerous studies analyzing this issue in Real World Evidence (RWE) populations[36,37]. The estimated frequency of active mental illness in patients with CHC assessed in the large cohort of American Veterans was as high as one-third, while in our analysis, the percentage of patients was 6.6%[38]. Among them, depression, addiction, and schizophrenia were the most common. On the other hand, the pooled prevalence of HCV infection among patients with severe psychiatric diseases evaluated in a meta-analysis that included papers from 1989-2020 was 8%, which is several times higher compared to the general population[38,39]. However, the fact that patients with mental illnesses are disproportionately affected by HCV is also influenced by other factors beyond the pathogenetic relationship. One that seems to be historical is exposure to infection through frequent contact with healthcare facilities, and it cannot be overlooked that hospitalizations for mental illness are very long. Another factor contributing to the higher prevalence of HCV infections in this population, the importance of which persists to the present day, is that persons diagnosed with mental disorders are much more likely to abuse substances, including injection drugs and needle sharing used for intravenous drug administration is the most common route of HCV transmission[17]. This was also documented in our analysis. Moreover, the population of HCV-infected patients with mental diseases, which was underserved in the era of IFN, has gained its opportunity in the time of DAA therapy. The much shorter course of treatment and the lack of contraindications to the drugs has enabled patients with psychiatric disorders to access therapy on the same principles as for other HCV-infected individuals and has provided a basis for predicting HCV microelimination in this population[18]. In the current analysis, we found no statistically significant differences in the course of treatment in mentally ill patients compared to others. The percentage of those who had their therapy modified or discontinued was comparable; the modification in both groups concerned only RBV dose reduction according to the label. The safety profile was also comparable with the percentage of patients experiencing SEAs and deaths. Similar conclusions on the good tolerability of DAA can be drawn from the observations of other researchers in RWE cohorts[40,41]. When analyzing psychiatric complications occurring during therapy, we found a significantly higher percentage of sleep disorders in patients with psychiatric diseases than in those without mental conditions. Other researchers evaluating the quality of sleep in patients with mental disorders did not find any significant differences during DAA therapy compared to the baseline, demonstrating that DAA regimens are free of mental side effects regardless of current and/or past psychiatric history[14,15].

In our analysis, however, in six patients, the underlying disease (five cases of depression and one of schizophrenia) worsened during antiviral therapy, which in 2 cases was the reason for discontinuing treatment. However, we cannot exclude the potential influence of other factors. It should be noted that the cited analyses were prospective, while ours is a retrospective study with limitations in data collection. Interestingly, another prospective study reported some degree of neuropsychiatric impairment associated with IFN-free treatment in 10 cirrhotic patients, suggesting their susceptibility to mild DAA neurotoxicity[42].

Despite the significant change in access to treatment, there are still some challenges for a group of patients with mental illness. These are related to potential drug interactions. For this reason, this is carefully reviewed before therapy, and if there are contraindications to combining medications, psychiatric drugs are modified to allow the patient to receive antiviral treatment. This is not always possible; in our study, three patients were on carbamazepine, which could not be discontinued as it was the only drug that stabilized their mental state. Although this drug is not recommended in combination with DAA because it can reduce their levels below therapeutic levels, all patients completed the treatment as planned without AEs and achieved SVR. It should be emphasized that a possible modification in psychiatric treatment in case of expected drug interactions, as well as monitoring the mental state of the patient, requires the cooperation of a hepatologist and a psychiatrist. However, the scope of supervision is significantly smaller than in the case of IFN-based therapy[17,43]. The issue we highlighted in our analysis was the significantly higher percentage of patients lost to follow-up without SVR evaluation in the population of patients with mental illness compared to those without mental disorders, 4.2% *vs* 2.5%, respectively. The problem with adherence, concerning not only the use of drugs which was not evaluated in our study but, as in this case, keeping the dates of follow-up visits, is also raised by other authors[18]. However, some analyses did not report the difference in adherence between mentally ill patients (including those with substance abuse disorder) and the general HCV-infected population[3,40,44].

In patients with available SVR, we did not observe significant differences in the effectiveness of DAA therapy depending on the diagnosis of mental illness, which is consistent with reports from other RWE cohorts[40,45]. A 96.9% cure rate was achieved in the mentally affected group compared to 97.7% in the patients without psychiatric disorders, despite a higher proportion of men, those with liver cirrhosis, and a higher prevalence of GT3 infection in this population, which are considered negative predictors of SVR in HCV-infected patients treated with DAA[21]. Significantly lower SVR rates have been documented in patients with bipolar disorder, which is consistent with the results of the analysis by Wedemeyer *et al*[18]. However, this multicenter study did not control for potential confounders, while in our research, the multivariate analysis clearly excluded bipolar disorder as an independent predictor of non-response to treatment. The identified independent negative predictors included the presence of liver cirrhosis, GT3 infection, history of prior therapy failure, and male gender, which is in line with available data concerning the general HCV-infected population[21,46]. However, apart from the abovementioned factors, administration of the ASV + DCV regimen or SOF/(VEL + RBV) combination was also associated with a lower chance of SVR. The ASV + DCV option was registered only for patients with GT1b infection and used until 2018. Due to its cumulative efficacy of 85%, evaluated in a meta-analysis of 9 clinical trials, it was considered suboptimal[23]. The SOF/(VEL + RBV) regimen is registered in patients with decompensated cirrhosis, and its efficacy in a randomized clinical trial was 83%[47]. In our analysis, 23/26 (88.5%) patients with mental disorders responded to this type of treatment. There are no papers evaluating this regimen exclusively in patients with mental illness, so we cannot relate our results to another study.

Our study has some limitations which we wish to stress. This is a retrospective study with all its consequences, such as incomplete data, including information on side effects, data entry errors, and possible bias. The database includes information from baseline to 12 wk after the end of therapy, and there are no data on the number of patients who had their psychiatric treatment modified before treatment, as well as the nature of these modifications. Additionally, no data were collected on the adjustment of psychiatric treatment during DAA therapy. Another limitation is the lack of systematic monitoring of the patient’s mental state, such as with appropriate questionnaires. The main strength of the current study is the large group of patients from different centers in our country treated in routine clinical practice, which affects the quality of the results and the possibility of generalizing conclusions. To the best of our knowledge, this is the first study to address the problem of treating CHC with various DAA regimens in patients with mental disorders, highlighting the differences in specific psychiatric illnesses.

**CONCLUSION**

This study provides real-world evidence for the effectiveness and safety of DAA treatment of HCV infection in patients with preexisting psychiatric disorders. As shown, most of these patients achieve SVR. No specific psychiatric diagnosis lowered the chance of successful DAA treatment. Negative predictors of virologic response do not differ for these patients compared to the general HCV-infected population and include cirrhosis, GT3 infection, male gender, and failure of previous therapy.

**ARTICLE HIGHLIGHTS**

***Research background***

In the era of interferon (IFN)-based therapies, patients with psychiatric disorders had limited access to therapy due to their unfavorable safety profile. This changed with the introduction of direct-acting antiviral (DAA) drugs.

***Research motivation***

We aimed to evaluate the tolerability and effectiveness of IFN-free therapies in patients with various psychiatric disorders and to identify predictors of virologic response in this patient population.

***Research objectives***

Data of 14272 patients treated with IFN-free regimens for chronic hepatitis C included in the EpiTer-2 database were analyzed. The patients were divided into two groups: 942 patients with mental disorders and 13330 without psychiatric diseases.

***Research methods***

The effectiveness and safety of antiviral treatment were compared between both populations. Effectiveness was assessed by the percentage of patients with sustained virologic response (SVR). Multiple logistic regression was used to predict the odds of no SVR in patients with mental illness. Safety data were collected through the treatment period and 12 wk of follow-up.

***Research results***

The cure rate was not significantly different in the two groups analyzed, with an SVR of 96.9% in patients with psychiatric disorders and 97.7% without psychiatric disorders. Patients with bipolar disorder achieved a lower SVR (90.5%), but multivariate analysis excluded it as an independent predictor of treatment non-response. Male gender, genotype 3 infection, cirrhosis and failure of previous therapy were identified as independent negative predictors. The percentage of patients who completed the planned therapy did not differ between the groups with and without mental disorders. In six patients, symptoms of mental illness (depression, schizophrenia) worsened, of which two discontinued treatment for this reason. New episodes of sleep disorders occurred significantly more often in patients with mental disorders. Patients with mental illness were more frequently lost to follow-up (4.2% *vs* 2.5%).

***Research conclusions***

DAA treatment is safe and effective in hepatitis C virus (HCV)-infected patients with mental disorders. No specific psychiatric diagnosis lowered the chance of successful antiviral treatment.

***Research perspectives***

The data obtained provide real-world evidence of the effectiveness and safety of DAA for HCV infection in patients with mental disorders, indicating that there are no differences compared with the general HCV-infected population.

**REFERENCES**

1 **Centers for Disease Control and Prevention**. Global Viral Hepatitis: Millions of People are Affected. [cited 8 March 2023]. Available from: https://www.cdc.gov/hepatitis/global/index.htm

2 **Lavanchy D**. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect* 2011; **17**: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]

3 **Gutiérrez-Rojas L**, de la Gándara Martín JJ, García Buey L, Uriz Otano JI, Mena Á, Roncero C. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. *Gastroenterol Hepatol* 2023; **46**: 382-396 [PMID: 35718017 DOI: 10.1016/j.gastrohep.2022.06.001]

4 **Roncero C**, Littlewood R, Vega P, Martinez-Raga J, Torrens M. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. *Eur J Gastroenterol Hepatol* 2017; **29**: 629-633 [PMID: 28230562 DOI: 10.1097/MEG.0000000000000855]

5 **Rifai MA**, Gleason OC, Sabouni D. Psychiatric care of the patient with hepatitis C: a review of the literature. *Prim Care Companion J Clin Psychiatry* 2010; **12** [PMID: 21494349 DOI: 10.4088/PCC.09r00877whi]

6 **Faccioli J**, Nardelli S, Gioia S, Riggio O, Ridola L. Neurological and psychiatric effects of hepatitis C virus infection. *World J Gastroenterol* 2021; **27**: 4846-4861 [PMID: 34447230 DOI: 10.3748/wjg.v27.i29.4846]

7 **Adinolfi LE**, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. *World J Gastroenterol* 2015; **21**: 2269-2280 [PMID: 25741133 DOI: 10.3748/wjg.v21.i8.2269]

8 **Mathew S**, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Fatima K, Qadri I. Hepatitis C virus and neurological damage. *World J Hepatol* 2016; **8**: 545-556 [PMID: 27134702 DOI: 10.4254/wjh.v8.i12.545]

9 **Davoodi L**, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. *Exp Ther Med* 2018; **16**: 971-978 [PMID: 30116347 DOI: 10.3892/etm.2018.6255]

10 **McGlynn EA**, Adams JL, Kramer J, Sahota AK, Silverberg MJ, Shenkman E, Nelson DR. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. *JAMA Netw Open* 2019; **2**: e194765 [PMID: 31173117 DOI: 10.1001/jamanetworkopen.2019.4765]

11 **Niederau C**, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, Moog G, Pape S, Weber B, Isernhagen K, Sandow P, Bokemeyer B, Alshuth U, Steffens H, Hüppe D. Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3. *PLoS One* 2014; **9**: e107592 [PMID: 25238535 DOI: 10.1371/journal.pone.0107592]

12 **Schäfer A**, Scheurlen M, Weissbrich B, Schöttker K, Kraus MR. Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? *Chemotherapy* 2007; **53**: 292-299 [PMID: 17496415 DOI: 10.1159/000102584]

13 **Elsherif O**, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. *PLoS One* 2017; **12**: e0178398 [PMID: 28636638 DOI: 10.1371/journal.pone.0178398]

14 **Fabrazzo M**, Zampino R, Vitrone M, Sampogna G, Del Gaudio L, Nunziata D, Agnese S, Santagata A, Durante-Mangoni E, Fiorillo A. Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. *Brain Sci* 2020; **10** [PMID: 32726940 DOI: 10.3390/brainsci10080483]

15 **Sundberg I**, Lannergård A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. *BMC Psychiatry* 2018; **18**: 157 [PMID: 29843679 DOI: 10.1186/s12888-018-1735-6]

16 **Janjua NZ**, Wong S, Darvishian M, Butt ZA, Yu A, Binka M, Alvarez M, Woods R, Yoshida EM, Ramji A, Feld J, Krajden M. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. *J Viral Hepat* 2020; **27**: 781-793 [PMID: 32187430 DOI: 10.1111/jvh.13295]

17 **Sockalingam S**, Sheehan K, Feld JJ, Shah H. Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals. *Am J Psychiatry* 2015; **172**: 512-516 [PMID: 26029803 DOI: 10.1176/appi.ajp.2015.14081041]

18 **Wedemeyer H**, Di Marco V, Garcia-Retortillo M, Teti E, Fraser C, Morano Amado LE, Rodriguez-Tajes S, Acosta-López S, O'Loan J, Milella M, Buti M, Guerra-Veloz MF, Ramji A, Fenech M, Martins A, Borgia SM, Vanstraelen K, Mertens M, Hernández C, Ntalla I, Ramroth H, Milligan S. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders. *Viruses* 2022; **14** [PMID: 36423102 DOI: 10.3390/v14112493]

19 **European Association for the Study of the Liver.** Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

20 **University of Liverpool**. Liverpool HEP Interactions. [cited 8 March 2023]. Available from: https://www.hep-druginteractions.org/

21 **Pabjan P**, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? *Viruses* 2022; **14**: 96 [PMID: 35062302 DOI: 10.3390/v14010096]

22 **Brzdęk M**, Zarębska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M, Janocha-Litwin J, Mazur W, Dybowska D, Berak H, Parfieniuk-Kowerda A, Klapaczyński J, Sitko M, Sobala-Szczygieł B, Piekarska A, Flisiak R. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. *World J Gastroenterol* 2023; **29**: 2015-2033 [PMID: 37155527 DOI: 10.3748/wjg.v29.i13.2015]

23 **Nguyen Thi Thu P**, Ngo Thi Quynh M, Pham Van L, Nguyen Van H, Nguyen Thanh H. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. *Biomed Res Int* 2022; **2022**: 6054677 [PMID: 35572735 DOI: 10.1155/2022/6054677]

24 **Xie J**, Xu B, Wei L, Huang C, Liu W. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis. *Infect Dis Ther* 2022; **11**: 1661-1682 [PMID: 35749010 DOI: 10.1007/s40121-022-00666-0]

25 **Ho SB**, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. *Am J Gastroenterol* 2001; **96**: 157-164 [PMID: 11197246 DOI: 10.1111/j.1572-0241.2001.03468.x]

26 **Trask PC**, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. *J Clin Oncol* 2000; **18**: 2316-2326 [PMID: 10829053 DOI: 10.1200/JCO.2000.18.11.2316]

27 **Juszczyk J**, Baka-Cwierz B, Beniowski M, Berak H, Bolewska B, Boroń-Kaczmarska A, Cianciara J, Cieśla A, Dziambor A, Gasiorowski J, Gietka A, Gliwińska E, Gładysz A, Gonciarz Z, Halota W, Horban A, Inglot M, Janas-Skulina U, Janczewska-Kazek E, Jaskowska J, Jurczyk K, Knysz B, Kryczka W, Kuydowicz J, Lakomy EA, Logiewa-Bazger B, Lyczak A, Mach T, Mazur W, Michalska Z, Modrzewska R, Nazzal K, Pabjan P, Piekarska A, Piszko P, Sikorska K, Szamotulska K, Sliwińska M, Swietek K, Tomasiewicz K, Topczewska-Staubach E, Trocha H, Wasilewski M, Wawrzynowicz-Syczewska M, Wrodycki W, Zarebska-Michaluk D, Zejc-Bajsarowicz M. [Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)]. *Przegl Epidemiol* 2005; **59**: 651-660 [PMID: 16433307]

28 **Raison CL**, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiatry* 2005; **66**: 41-48 [PMID: 15669887 DOI: 10.4088/jcp.v66n0106]

29 **Drozdz W**, Borkowska A, Wilkosc M, Halota W, Dybowska D, Rybakowski JK. Chronic paranoid psychosis and dementia following interferon-alpha treatment of hepatitis C: a case report. *Pharmacopsychiatry* 2007; **40**: 146-148 [PMID: 17694476 DOI: 10.1055/s-2007-984390]

30 **Lotrich F**. Management of Psychiatric Disease in Hepatitis C Treatment Candidates. *Curr Hepat Rep* 2010; **9**: 113-118 [PMID: 20871787 DOI: 10.1007/s11901-010-0035-5]

31 **Quelhas R**, Lopes A. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. *J Psychiatr Pract* 2009; **15**: 262-281 [PMID: 19625882 DOI: 10.1097/01.pra.0000358313.06858.ea]

32 **Goñi Esarte S**, Juanbeltz R, Martínez-Baz I, Castilla J, San Miguel R, Herrero JI, Zozaya JM. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. *Rev Esp Enferm Dig* 2019; **111**: 445-452 [PMID: 31066286 DOI: 10.17235/reed.2019.6063/2018]

33 **Zarebska-Michaluk DA**, Lebensztejn DM, Kryczka WM, Skiba E. Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. *Adv Med Sci* 2010; **55**: 67-73 [PMID: 20371429 DOI: 10.2478/v10039-010-0009-4]

34 **Yarlott L**, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders - A review. *J Adv Res* 2017; **8**: 139-148 [PMID: 28149649 DOI: 10.1016/j.jare.2016.09.005]

35 **Więdłocha M**, Marcinowicz P, Sokalla D, Stańczykiewicz B. The neuropsychiatric aspect of the HCV infection. *Adv Clin Exp Med* 2017; **26**: 167-175 [PMID: 28397449 DOI: 10.17219/acem/37787]

36 **Perry W**, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. *Dig Dis Sci* 2008; **53**: 307-321 [PMID: 17703362 DOI: 10.1007/s10620-007-9896-z]

37 **Butt AA**, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. *J Viral Hepat* 2007; **14**: 890-896 [PMID: 18070293 DOI: 10.1111/j.1365-2893.2007.00885.x]

38 **el-Serag HB**, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. *Gastroenterology* 2002; **123**: 476-482 [PMID: 12145801 DOI: 10.1053/gast.2002.34750]

39 **Braude MR**, Phan T, Dev A, Sievert W. Determinants of Hepatitis C Virus Prevalence in People With Serious Mental Illness: A Systematic Review and Meta-Analysis. *J Clin Psychiatry* 2021; **83** [PMID: 34905666 DOI: 10.4088/JCP.21r14079]

40 **Fiore V**, De Vito A, Colpani A, Manca V, Maida I, Madeddu G, Babudieri S. Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free. *Life (Basel)* 2022; **12** [PMID: 36431008 DOI: 10.3390/life12111873]

41 **de Gennaro N**, Diella L, Monno L, Angarano G, Milella M, Saracino A. Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. *BMC Infect Dis* 2020; **20**: 196 [PMID: 32138757 DOI: 10.1186/s12879-020-4922-2]

42 **Volpato S**, Montagnese S, Zanetto A, Turco M, De Rui M, Ferrarese A, Amodio P, Germani G, Senzolo M, Gambato M, Russo FP, Burra P. Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. *BMJ Open Gastroenterol* 2017; **4**: e000183 [PMID: 29333276 DOI: 10.1136/bmjgast-2017-000183]

43 **Chasser Y**, Kim AY, Freudenreich O. Hepatitis C Treatment: Clinical Issues for Psychiatrists in the Post-Interferon Era. *Psychosomatics* 2017; **58**: 1-10 [PMID: 27871760 DOI: 10.1016/j.psym.2016.09.004]

44 **DiMatteo MR**, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000; **160**: 2101-2107 [PMID: 10904452 DOI: 10.1001/archinte.160.14.2101]

45 **Back D**, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. *J Viral Hepat* 2019; **26**: 951-960 [PMID: 30977945 DOI: 10.1111/jvh.13110]

46 **Wang HL**, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. *J Gastroenterol Hepatol* 2017; **32**: 45-52 [PMID: 27597318 DOI: 10.1111/jgh.13587]

47 **Curry MP**, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med* 2015; **373**: 2618-2628 [PMID: 26569658 DOI: 10.1056/NEJMoa1512614]

**Footnotes**

**Institutional review board statement:** According to local law (Pharmaceutical law of 6th September 2001, art.37al), non-interventional studies do not require ethics committee approval.

**Informed consent statement:** All study participants provided informed consent for antiviral treatment and processing of personal data according to the requirements of the therapeutic program.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** Dataset available upon reasonable request to the corresponding author at dorota1010@tlen.pl.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Polish Association of Hepatology; Polish Society of Epidemiologists and Infectiologists.

**Peer-review started:** March 23, 2023

**First decision:** March 28, 2023

**Article in press:** April 28, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Isakov V, Russia; Liu CH, Taiwan **S-Editor:** Wang JJ **L-Editor:** Webster JR **P-Editor:** Zhao S

**Figure Legends**



**Figure 1** **The sustained virological response rate in the group with mental disorders compared to the control group in intention-to-treat and per protocol analyses and calculated per protocol analysis in the population with mental disorders.** A: The sustained virological response rate (SVR) in the group with mental disorders (*n* = 942) compared to the control group (*n* = 13330) in intention-to-treat and per protocol analyses; B: SVR calculated per protocol analysis in the population with mental disorders considering the type of the psychiatric illness in comparison to the control group. All statistical comparisons were performed with Pearson’s chi-square or Fisher’s exact test. ITT: Intention-to-treat; PP: Per protocol.

**Table 1 Baseline characteristics of chronic hepatitis C patients with (group A) and without (group B) psychiatric disorders, (%) n**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **All patients (*n* = 14272)** | **Group A (*n* = 942)** | **Group B (*n* = 13330)** | ***P* value** |
| Age, mean (min-max yr) | 51.2 (18-92) | 50.8 (19-90) | 51.2 (18-92) | 0.599 (*U* = 6216478) |
| Men/women | 49.3/50.7 (7035/7237) | 54.9/45.1, 507/435 | 49.0/51.0, 6528/6802 | 0.004 (*χ2* = 8.3) |
| BMI, mean (SD) | 26.2 (4.5) | 26.9 (5.1) | 26.1 (4.5) | 0.0001 (*U* = 5811710) |
| BMI ≥ 30 | 17.4 (2486) | 23.9 (225) | 17.0 (2261) | < 0.0001 (*χ2* = 29.4) |
| Comorbidities |  |  |  |  |
| Hypertension | 32.0 (4567) | 34.4 (324) | 31.8 (4243) | 0.103 (*χ2* = 2.6) |
| Diabetes | 11.3 (1614) | 13.0 (122) | 11.2 (1492) | 0.100 (*χ2* = 0.5) |
| Renal disease | 3.8 (543) | 3.4 (32) | 3.8 (511) | 0.498 (*χ2* = 0.5) |
| Autoimmune disease | 2.1 (304) | 2.0 (19) | 2.1 (285) | 0.803 (*χ2* = 0.06) |
| Non-HCC tumor | 2.0 (279) | 2.1 (20) | 1.9 (259) | 0.700 (*χ2* = 0.15) |
| ALT (IU/L), median (IQR) | 58.0 (37.0-97.0) | 59.0 (36.0-96.0) | 58.0 (37.0-97.0) | 0.581 (*U* = 6204221) |
| Albumin (g/dL), median (IQR) | 4.1 (3.8-4.4) | 4.1 (3.8-4.4) | 4.1 (3.8-4.4) | 0.633 (*U* = 6222478) |
| Bilirubin (mg/dL), median (IQR) | 0.6 (0.5-0.9) | 0.6 (0.5-0.9) | 0.6 (0.5-0.9) | 0.060 (*U* = 6050856) |
| Hemoglobin (g/dL), median (IQR) | 14.5 (13.4-15.5) | 14.4 (13.4-15.4) | 14.5 (13.4-15.6) | 0.307 (*U* = 6120464) |
| Platelets (× 1000/μL), median (IQR) | 197.0 (146.0-244.0) | 190.0 (136.0-240.0) | 197.0 (146.0-244.0) | 0.01 (*U* = 597757) |
| Creatinine (mg/dL), median (IQR) | 0.8 (0.7-0.9) | 0.8 (0.7-0.9) | 0.8 (0.7-0.9) | 0.798 (*U* = 6101372) |
| HCV RNA, × 106 IU/mL, median (IQR) | 0.97 (0.32-2.53) | 1.17 (0.38-3.0) | 0.96 (0.31-2.48) | 0.0005 (*U* = 5856849) |

The reported *P*-value relates to Pearson’s chi-square test (or Fisher’s exact test if the number of observations in a category was less than 10) or the Mann-Whitney *U* test. BMI: Body mass index; ALT: Alanine transaminase; HCC: Hepatocellular carcinoma; IQR: Interquartile range; HCV: Hepatitis C virus; RNA: Ribonucleic acid.

**Table 2 Characteristics of liver disease in patients with chronic hepatitis C with (group A) and without (group B) psychiatric disorders, (%) n**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameters** | **All patients (*n* = 14272)** | **Group A (*n* = 942)** | **Group B (*n* = 13330)** | ***P* value** |
| Genotype |  |  |  |  |
| 1a | 4.4 (633) | 4.1 (39) | 4.5 (594) | 0.649 (*χ2* = 0.2) |
| 1b | 77.3 (11029) | 67.8 (639) | 77.9 (10390) | < 0.0001 (*χ2* = 51.2) |
| 1 | 2.1 (303) | 2.4 (23) | 2.1 (280) | 0.483 (*χ2* = 0.5) |
| 2 | 0.2 (29) | 0.2 (2) | 0.2 (27) | > 0.948 (*χ2* = 0.004) |
| 3 | 11.1 (1580) | 17.5 (165) | 10.6 (1415) | < 0.0001 (*χ2* = 42.6) |
| 4 | 4.9 (695) | 8.0 (74) | 4.7 (621) | < 0.0001 (*χ2* = 19.4) |
| 5 | 0.007 (1) | 0.0 (0) | 0.007 (1) | 1.0 |
| 6 | 0.01 (2) | (0.0) 0 | 0.01 (2) | 1.012 |
| Liver fibrosis |  |  |  |  |
| F0 | 2.5 (361) | 1.4 (13) | 2.6 (348) | 0.02 (*χ2* = 5.4) |
| F1 | 40.8 (5831) | 34.8 (328) | 41.3 (5503) | < 0.0001 (*χ2* = 15.2) |
| F2 | 19.2 (2743) | 21.0 (198) | 19.1 (2545) | 0.147 (*χ2* = 2.1) |
| F3 | 13.5 (1925) | 13.2 (124) | 13.5 (1801) | 0.763 (*χ2* = 0.09) |
| F4 | 23.9 (3412) | 29.6 (279) | 23.5 (3133) | < 0.0001 (*χ2* = 18.1) |
| Child-Pugh |  |  |  |  |
| Child-Pugh-B | 2.8 (398) | 4.4 (41) | 2.7 (357) | 0.003 (*χ2* = 9.1) |
| Child-Pugh-C | 0.2 (23) | 0.4 (4) | 0.1 (19) | 0.061 |
| HCC history | 1.3 (191) | 1.2 (11) |  1.3 (180) | 0.637 (*χ2* = 0.2) |
| Coinfection |  |  |  |  |
| HIV | 5.9 (848) | 9.1 (86) | 5.7 (762) | < 0.0001 (*χ2* = 18.4) |
| HBV | 13.5 (1933) | 17.5 (165) | 13.3 (1768) | 0.0002 (*χ2* = 13.6) |
| HIV/HBV | 1.6 (225) | 3.4 (32) | 1.4 (193) | < 0.0001 (*χ2* = 21.6) |

The reported *P*-value relates to Pearson’s chi-square test or Fisher’s exact test if the number of observations in the category was less than 10. HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus.

**Table 3 Treatment characteristics in chronic hepatitis C patients with (group A) and without (group B) psychiatric disorders, (%) n**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **All patients (*n* = 14272)** | **Group A (*n* = 942)** | **Group B (*n* = 13330)** | ***P* value** |
| History of antiviral treatment |  |  |  |  |
| Treatment-naïve | 78.7 (11238) | 80.6 (760) | 78.6 (10478) | 0.132 (*χ2* = 2.2) |
| Nonresponder to IFN-based regimens | 19.6 (2791) | 16.7 (157) | 19.8 (2634) | 0.02 (*χ2* = 5.3) |
| Nonresponder to IFN-free regimens | 1.7 (247) | 2.7 (25) | 1.6 (222) | 0.02 (*χ2* = 5.1) |
| Current treatment regimen |  |  |  |  |
| Pangenotypic regimens | 35.2 (5028) | 43.0 (405) | 34.7 (4619) | < 0.0001 (*χ2* = 26.0) |
| Genotype-specific regimens | 64.8 (9248) | 57.0 (537) | 65.3 (8711) |
| Current-RBV-containing regimens | 16.2 (2308) | 16.5 (155) | 16.1 (2153) | 0.807 (*χ2* = 0.05) |
| Genotype-specific treatment regimens |  |  |  |  |
| ASV + DCV | 0.8 (118) | 1.3 (12) | 0.8 (106) | 0.117 (*χ2* = 2.5) |
| SOF/LDV ± RBV | 19.6 (2795) | 21.8 (205) | 19.4 (2590) | 0.081 (*χ2* = 3.1) |
| OBV/PTV/r ± DSV ± RBV | 25.4 (3626) | 14.1 (133) | 26.2 (3493) | < 0.0001 (*χ2* = 67.8) |
| GZR/EBR ± RBV | 16.8 (2400) | 16.3 (154) | 16.8 (2246) | 0.691 (*χ2* = 0.1) |
| Other SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV | 2.2 (305) | 3.2 (33) | 2.1 (272) | 0.02 (*χ2* = 5.7) |
| Pangenotypic regimens |  |  |  |  |
| GLE/PIB | 20.6 (2940) | 20.6 (194) | 20.6 (2746) | 0.997 (*χ2* = 0.0) |
| GLE/PIB + SOF + RBV | 0.05 (6) | 0.0 (0) | 0.05 (6) | 1.0 |
| SOF/VEL ± RBV | 14.4 (2058) | 22.2 (209) | 13.9 (1849) | < 0.0001 (*χ2* = 49.3) |
| SOF/VEL/VOX | 0.2 (24) | 0.2 (2) | 0.2 (22) | 0.670 |

The reported *P*-value relates to Pearson’s chi-square test or Fisher’s exact test if the number of observations in the category was less than 10. CHC: Chronic hepatitis C; IFN: Interferon; RBV: Ribavirin; ASV: Asunaprevir; DCV: Daclatasvir; LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir; r: Ritonavir; DSV: Dasabuvir; GZR: Grazoprevir; EB: Elbasvir; SMV: Simeprevir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir; VOX: Voxilaprevir.

**Table 4 Logistic multiple regression results on the association between lack of sustained viral response, bipolar disorder (for which lower frequency of sustained viral response was observed in the present study), and known risk factors of non-response to antiviral treatment in the studied cohort (*n* = 14272)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **OR** | **95%CI** | ***P* value** |
| Bipolar disorder | 3.52 | 0.76-16.34 | 0.109 |
| Male sex | 1.93 | 1.51-2.45 | < 0.0001 |
| Obesity (BMI > 30 kg/m2) | 1.08 | 0.82-1.43 | 0.579 |
| GT3 | 3.26 | 2.50-4.27 | < 0.0001 |
| Cirrhosis | 2.55 | 2.01-3.22 | < 0.0001 |
| HIV-coinfection | 1.37 | 0.88-2.13 | 0.165 |
| HBV-coinfection | 0.85 | 0.61-1.18 | 0.323 |
| History of HCV-treatment failure | 1.46 | 1.14-1.87 | 0.003 |
| ASV+DCV | 4.97 | 2.60-9.55 | < 0.0001 |
| SOF/VEL | 0.86 | 0.61-1.20 | 0.371 |
| SOF/VEL+RBV | 2.37 | 1.34-4.17 | 0.003 |

BMI: Body mass index; GT: Genotype; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ASV: Asunaprevir; DCV: Daclatasvir; SOF: Sofosbuvir; VEL: Velpatasvir; RBV: Ribavirin; OR: Odds ratio; CI: Confidence interval.

**Table 5 Safety of direct-acting antiviral treatment in chronic hepatitis C patients with (group A) and without (group B) psychiatric disorders, (%) n**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **All patients (*n* = 14272)** | **Group A (*n* = 942)** | **Group B (*n* = 13330)** | ***P* value** |
| Treatment course |  |  |  |  |
| According to schedule | 97.5 (13848) | 96.8 (907) | 97.6 (12941) | 0.164 (*χ2* = 1.9) |
| Therapy discontinuation | 1.1 (157) | 1.4 (13) | 1.1 (144) | 0.394 (*χ2* = 0.7) |
| Therapy modification | 1.4 (194) | 1.8 (17) | 1.3 (177) | 0.222 (*χ2* = 1.5) |
| No data | 0.5 (73) | 0.5 (5) | 0.5 (68) | 0.813 |
| Death | 0.5 (71) | 0.4 (4) | 0.5 (67) | 1.0 |
| SAE | 1.0 (145) | 1.6 (15) | 0.97 (130) | 0.068 (*χ2* = 3.3) |
| Psychiatric complications |  |  |  |  |
| New incidence of depression | 0.1 (8) | 0.2 (2) | 0.05 (6) | 0.093 |
| New incidence of schizophrenia | 0.0 (1) | 0.0 (0) | 0.0 (1) | 1.0 |
| New incidence of sleep disorders | 1.8 (262) | 3.3 (31) | 1.7 (231) | 0.001 (*χ2* = 10.4) |
| New incidence of anxiety | 0.0 (1) | 0.1 (1) | 0.0 (0) | 1.0 |
| Drinking binge | 0.0 (1) | 0.1 (1) | 0.0 (0) | 1.0 |
| Exacerbation of psychiatric disease |  | 0.6 (6) |  |  |
| Depression |  | 0.5 (5) |  |  |
| Schizophrenia |  | 0.1 (1) |  |  |

The reported *P*-value relates to Pearson’s chi-square test or Fisher’s exact test if the number of observations in the category was less than 10. SAEs: Serious adverse events.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**